Purpose. The aim of this study was to determine the loading efficiency, physicochemical stability, and release of irinotecan-loaded DC BeadsTM (bead size 100—300 μm, 300—500 μm) before and after mixing with nonionic contrast medium (Accupaque® 300, Imeron® 300, Ultravist ® 300) during a prolonged period of time (28 days) when stored at room temperature or refrigerated. Methods. DC Beads TM were loaded with 50 mg irinotecan (Campto®) per milliliter beads in a 2 h loading period. Drug loading efficiency and stability were determined by measuring the irinotecan concentration in the excess solution. A free-flowing in vitro elution method for a period of 2 h and phosphate buffered solution (PBS, pH 7.2) as elution medium were used to analyze the integrity of the irinotecan-loaded. Stability of irinotecan-loaded beads after mixing with an equal volume of three different nonionic contrast agents was determined by measuring irinotecan concentrations in the excess solutions. Vials with loaded beads were stored protected from light at room temperature. Mixtures with contrast media were stored protected from light under refrigeration (2—8°C). Samples were taken periodically over a 4 week period (day 0, 1, 3, 7 and 28). A reversed phase HPLC assay with ultraviolet detection was utilized to analyze the concentration and purity of irinotecan. Results. The loading procedure of DC BeadsTM with irinotecan drug solution resulted in a loading percentage of 96% (bead size 100—300 μm) independent of the storage time. No differences in loading levels and no irinotecan degradation products were observed over the period of 28 days, while the test vials were stored light protected at room temperature. Integrity of loaded irinotecan was also given over that same period of time according to the purity and concentration of irinotecan measured after intentional elution with PBS. Mixing of irinotecan-loaded beads (bead size 100—300 μm, 300—500 μm) with nonionic contrast media decreased the irinotecan loading efficiency by ∼5—10% during a maximum period of 24 h. However, no further elution or degradation was observed during a 4-week period when stored protected from light under refrigeration. Conclusions. Irinotecan-loaded DC BeadsTM are shown to have adequate physicochemical stability over a period of at least 28 days when stored light protected at room temperature. Due to concerns of microbiological overgrowth refrigeration should always be considered. The preparation of admixtures of irinotecan-loaded beads with contrast medium in centralized cytotoxic preparation units is not recommended, because of rapid elution of 5—10% of irinotecan from the loaded beads. Furthermore, physicians see no advantages of admixtures due to the wide variation of mixing ratios of drug-loaded beads with contrast medium. In addition varying volumes of 0.9% sodium chloride solution are to be admixed during the chemoembolization procedure
[1]
Martin Meyer,et al.
Krebs in Deutschland 2003-2004 Häufigkeiten und Trends
,
2008
.
[2]
F. J. Ramos,et al.
Cetuximab and Chemotherapy for Patients with Unresectable CRC Liver Metastasis: Are We Changing the Natural Course of the Disease?
,
2007,
Oncology Research and Treatment.
[3]
J. Ferlay,et al.
Estimates of the cancer incidence and mortality in Europe in 2006.
,
2006,
Annals of oncology : official journal of the European Society for Medical Oncology.
[4]
J. Venkateswararao,et al.
Validated Reverse Phase HPLC Method for the Determination of Irinotecan in Pharmaceutical Dosage Forms
,
2007
.
[5]
A. Lewis,et al.
Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties.
,
2007,
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[6]
S. Zangos,et al.
Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update
,
2007,
European Radiology.
[7]
M. Victoria,et al.
Delivery of drugs from embolisation microspheres
,
2006
.
[8]
Frcsc Paul D. Greig MD,et al.
Survival After Hepatic Resection for Colorectal Metastases: A 10-Year Experience
,
2006,
Annals of Surgical Oncology.
[9]
P. Ruszniewski,et al.
Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours.
,
2005,
Best practice & research. Clinical gastroenterology.
[10]
N. Kemeny,et al.
An update on hepatic arterial infusion chemotherapy for colorectal cancer.
,
2003,
The oncologist.
[11]
I. Krämer,et al.
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags
,
2000
.
[12]
D. Craik,et al.
Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition.
,
1997,
Journal of pharmaceutical sciences.
[13]
K. Itoh,et al.
Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11
,
1995,
Japanese journal of cancer research : Gann.
[14]
A. Kawai,et al.
Kinetic Studies of the Hydrolysis and Lactonization of Camptothecin and Its Derivatives, CPT-11 and SN-38, in Aqueous Solution
,
1994
.
[15]
H. Kuga,et al.
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
,
1991,
Cancer research.